INNOTOX 50 units new liquid phase (botulinum toxin) type A – Medytox Inc.

Innotox Botulinum Toxin Type A

We ship this drug in a cold case with dry ice and cold preservation.

Innotox / INNOTOX 50 units. is an innovative drug (botulinum toxin) type A developed by the South Korean company Medytox Inc.

This drug has gained great popularity in clinics in South Korea and Japan due to several advantages:

1. Structure of the drug: Innotox is available in a new liquid phase, so it does not require dilution. One bottle contains a ready-made product solution for 50 units.
2. Composition: the improved formula of the preparation does not contain: proteins, albumin, gelatin, compared with other similar drugs.
3. Temperature conditions: insensitive to temperature extremes, in contrast to solid-phase preparations. However, it is recommended that you keep it in the refrigerator until use. The opened bottle can be stored in the refrigerator at a temperature of 2 to 8 degrees 72 hours.
4. Diffusion: has the least diffusion among all botulinum toxins currently known.
5. Effect: during the course of procedures, the effect lasts up to 8 months, in contrast to other botulinum toxins, in which the effect lasts up to 4 months.

The active components are: botulinum toxin type A, L-methionine, polysorbate 20, buffered saline phosphate pH 7.0.

Indications

• blepharospasm;
• hemifacial spasm;
• cervical dystonia (spastic torticollis);
• focal spasticity of the wrist and hand in stroke patients;
• paralytic strabismus (squint);
• local muscle spasm in cerebral palsy in children aged 2 years and older;
• correction of facial wrinkles.

ACTIVE COMPONENTS

• botulinum toxin type A,
• L-methionine,
• polysorbate 20,
• buffered saline phosphate pH 7.0.

CONTRAINDICATIONS, COMPLICATIONS, POSSIBLE SIDE EFFECTS:

• hypersensitivity to the components of the composition;
• pregnancy and lactation;
• inflammatory processes on the skin in the target area;
• bleeding disorders;
• herpes, as well as any infectious and chronic systemic diseases in the acute stage;
• fever;
• diabetes;
• oncological diseases;
• pronounced hernial protrusions on the lower and upper eyelids;
• myasthenia gravis (Myasthenia Gravis) – an autoimmune disease that causes chronic muscle fatigue syndrome;
• age before 18 and after 65 years.

MODE OF APPLICATION

A solution of the finished product is injected with a 30G needle at the rate of 4 units per 0.1 ml (regardless of the volume of syringe used).

Injections of the drug should be carried out by a qualified doctor who has undergone a training course.

Specifications 50iu

Brand INNOTOX

Place of Origin South Korea